Britain’s Most Admired... Health and household

In a bad year for pharma, GlaxoSmithKline is still on top but paying for poor sales of controversial diabetes treatment Avandia.

Last Updated: 09 Oct 2013

1. GlaxoSmithKline – 64.3
2. AstraZeneca – 60.6
3. Reckitt Benckiser – 59.1
4. Smith & Nephew – 58.5
5. Shire – 54.8

Third-quarter profits are down 4% to £1.88bn, with £700m annual cost cuts announced. CEO-in-waiting Andrew Witty has his work cut out. Second-placed AstraZeneca is similarly beleaguered, announcing a 7% fall in third-quarter profits, with patent battles looming over its top-selling products. Acquisitions costs related to the £15bn purchase of American biotechnology firm Medimmune have hit hard. Bronze medalists: at Reckitt Benckiser, year-to-date net revenue grew by 11% in the third quarter, and full year targets have been raised. Growth was driven by new products and a boom – thank you, British weather – in Nurofen and Strepsils.

Find this article useful?

Get more great articles like this in your inbox every lunchtime

Is it favouritism to protect an employee no one likes?

The Dominic Cummings affair shows the dangers of double standards, but it’s also true that...

Masterclass: Communicating in a crisis

In this video, Moneypenny CEO Joanna Swash and Hill+Knowlton Strategies UK CEO Simon Whitehead discuss...

Remote working forever? No thanks

EKM's CEO Antony Chesworth has had no problems working from home, but he has no...

5 rules for work-at-home productivity

And how to focus when focusing feels impossible.

Scandal management lessons from Dominic Cummings

The PR industry offers its take on the PM’s svengali.

Why emails cause conflict

And what you can do about it.